Some research suggests that share may be as high as two-thirds. Yet relatively few older Americans have private long-term ...
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results